Compare SYSCO Corporation (SYY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SYSCO Corporation vs TG Therapeutics Inc — how do they compare? SYSCO Corporation trades at $81.33 (market cap $38.63B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: SYSCO Corporation is far larger — about 4.7× TG Therapeutics Inc's market cap, and SYSCO Corporation pays a 2.72% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SYY | TGTX | |
|---|---|---|
Market Cap | $38.63B | $8.26B |
Sector | Consumer Staples | Health |
52-Week High | $91.16 | $59.06 |
52-Week Low | $69.30 | $26.39 |
Enterprise Value | $52.11B | $8.50B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYY trades at $81.22, down 0.58% on the day, with a bullish technical signal supported by moving averages. The company reported mixed Q1 2026 earnings, missing EPS expectations of $0.945 with $0.94, but maintains strong revenue growth, reaching $81.37B in 2025. Analyst consensus is bullish with a $84.75 price target, and the upcoming Q4 2026 earnings report on August 4 is a key catalyst. Recent news highlights operational efficiency gains and AI integration, including a Newsweek AI Impact Award.
SYY presents a moderate buy opportunity with upside to the consensus target, supported by stable cash flow and dividend payments. Risks include thin net margins of 2.08% and elevated debt levels, with long-term debt at $11.51B. The stock's valuation is reasonable with a P/E of 22.44, but margin pressure and economic sensitivity in the food distribution sector warrant caution.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
